Technical Analysis for ROSGQ - Rosetta Genomics Ltd

Grade Last Price % Change Price Change
grade D 0.0124 -18.42% -0.0028
ROSGQ closed down 18.42 percent on Friday, July 31, 2020, on 1 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical ROSGQ trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Fell Below 20 DMA Bearish -18.42%
Bollinger Band Squeeze Range Contraction -18.42%
Narrow Range Bar Range Contraction -18.42%
Wide Bands Range Expansion -18.42%
Gapped Down Weakness -18.42%
Older signals for ROSGQ ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.
RTT Branches Of Biology Cancer Oncology Prostate Cancer Tumor Diagnostic Tests Infectious Causes Of Cancer Melanoma Bladder Cancer Non Small Cell Lung Cancer Genetics Metastatic Cancer Hybridization

Is ROSGQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 0.05
52 Week Low 0.0016
Average Volume 18,961
200-Day Moving Average 0.0116
50-Day Moving Average 0.0212
20-Day Moving Average 0.0166
10-Day Moving Average 0.0161
Average True Range 0.0068
ADX 22.6
+DI 29.1800
-DI 23.6422
Chandelier Exit (Long, 3 ATRs ) 0.0096
Chandelier Exit (Short, 3 ATRs ) 0.0304
Upper Bollinger Band 0.0239
Lower Bollinger Band 0.0093
Percent B (%b) 0.21
BandWidth 87.9518
MACD Line -0.0017
MACD Signal Line -0.0016
MACD Histogram -0.0001
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0124
Resistance 3 (R3) 0.0124 0.0124 0.0124
Resistance 2 (R2) 0.0124 0.0124 0.0124 0.0124
Resistance 1 (R1) 0.0124 0.0124 0.0124 0.0124 0.0124
Pivot Point 0.0124 0.0124 0.0124 0.0124 0.0124
Support 1 (S1) 0.0124 0.0124 0.0124 0.0124 0.0124
Support 2 (S2) 0.0124 0.0124 0.0124 0.0124
Support 3 (S3) 0.0124 0.0124 0.0124
Support 4 (S4) 0.0124